---
id: 241
title: Klebsiella pneumoniae
category: organisms
subcategory: gram_negative_rods
tags: [Klebsiella, ESBL, CRE, KPC, pneumonia, alcoholic]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Klebsiella pneumoniae*? Use **"Alcoholic Pneumonia (Currant Jelly), ESBL/CRE Common, Carbapenem First-Line if Resistant"** framework.

## Answer

### **Key Clinical Syndromes:**

**Pneumonia:**
- **"Classic" alcoholic pneumonia** (lobar, upper lobe)
- **"Currant jelly" sputum** (thick, bloody, mucoid)
- **Necrotizing pneumonia, lung abscess**
- **High mortality** (30-50% if bacteremic)

**Urinary Tract Infections:**
- **Healthcare-associated UTI** (catheters, instrumentation)
- **Community-acquired** (diabetes, elderly)

**Bacteremia/Sepsis:**
- **Often from pulmonary or GU source**
- **High mortality** (20-40%)

**Intra-Abdominal Infections:**
- **Cholangitis, liver abscess** (especially in Asia)
- **Peritonitis, IAI**

**Pyogenic Liver Abscess:**
- **Hypermucoviscous strains** (K1, K2 serotypes)
- **Common in Asia** (diabetes, biliary disease)
- **Metastatic complications:** Endophthalmitis, meningitis, necrotizing fasciitis

### **Antimicrobial Resistance:**

**ESBL (Extended-Spectrum Beta-Lactamase):**
- **15-30%** of *K. pneumoniae* in US (higher in healthcare settings)
- **Resistance to:** Penicillins, cephalosporins (including 3rd-generation)
- **Treat with:** Carbapenems

**CRE (Carbapenem-Resistant Enterobacterales):**
- **KPC (Klebsiella pneumoniae carbapenemase)** - most common mechanism in US
- **NDM, OXA-48** (other carbapenemases)
- **Very limited options:**
  - Ceftazidime-avibactam 2.5g IV q8h
  - Meropenem-vaborbactam 4g IV q8h
  - Imipenem-cilastatin-relebactam 1.25g IV q6h
  - Colistin (last resort, nephrotoxic)

**Hypervirulent *K. pneumoniae* (hvKP):**
- **Hypermucoviscous phenotype** (string test positive, >5 mm viscous strand)
- **Often community-acquired** (unlike typical *Klebsiella*)
- **Metastatic spread** (liver abscess → endophthalmitis, meningitis)
- **Typically antibiotic-susceptible** (but can acquire resistance)

### **Treatment by Syndrome:**

**Community-Acquired Pneumonia:**
- **Ceftriaxone 2g IV daily** (if susceptible)
- **If ESBL suspected:** Meropenem 1g IV q8h OR ertapenem 1g IV daily
- **Duration:** 7-10 days

**Healthcare-Associated Pneumonia/HAP:**
- **Empiric:** Pip-tazo 4.5g IV q6h OR cefepime 2g IV q8h
- **If ESBL/CRE:** Meropenem 1g IV q8h OR newer beta-lactam/beta-lactamase inhibitor combinations

**Bacteremia/Sepsis:**
- **Ceftriaxone 2g IV daily** (if susceptible)
- **If ESBL:** Meropenem 1g IV q8h OR ertapenem 1g IV daily
- **If CRE:** Ceftazidime-avibactam, meropenem-vaborbactam, or combination therapy
- **Duration:** 10-14 days

**UTI/Pyelonephritis:**
- **Ceftriaxone 1-2g IV daily** (if susceptible)
- **If ESBL:** Ertapenem 1g IV daily OR meropenem 1g IV q8h
- **Duration:** 7-14 days

**Pyogenic Liver Abscess:**
- **Ceftriaxone 2g IV daily** × 4-6 weeks (often susceptible if hvKP)
- **Drainage** if large (>5 cm) or no response
- **Screen for metastatic complications:** Ophthalmology exam (endophthalmitis), MRI brain (if CNS symptoms)

**CRE Infections:**
- **Ceftazidime-avibactam 2.5g IV q8h** (KPC-producing CRE)
- **Meropenem-vaborbactam 4g IV q8h** (KPC-producing CRE)
- **Imipenem-cilastatin-relebactam 1.25g IV q6h**
- **Consider combination therapy** if severe (e.g., ceftazidime-avibactam + aztreonam for metallo-beta-lactamases)

### **Virulence Factors:**

**Capsule:**
- **Antiphagocytic** (K serotypes K1, K2 most virulent)

**Hypermucoviscosity:**
- **Hypermucoviscous hvKP** (thick capsule, resists phagocytosis, causes metastatic spread)

**Siderophores:**
- **Iron acquisition** (aerobactin, yersiniabactin)

### **Special Considerations:**

**Alcoholics:**
- **Increased risk** of *Klebsiella* pneumonia
- **Upper lobe involvement** (mimics TB)
- **"Currant jelly" sputum** (highly suggestive)

**Diabetes:**
- **Increased risk** of pyogenic liver abscess (hvKP)

**CRE Screening:**
- **High-risk patients:** Previous CRE, recent hospitalization abroad, long-term care
- **Rectal swab** for surveillance

**Infection Control:**
- **Contact precautions** (CRE)
- **Cohorting** (prevent transmission)

## Key Points

### **Alcoholic Pneumonia:**
- **"Currant jelly" sputum** (thick, bloody, mucoid)
- **Upper lobe, necrotizing**

### **ESBL/CRE Common:**
- **ESBL 15-30%** (healthcare settings higher)
- **CRE emerging** (KPC most common in US)

### **Carbapenem First-Line if ESBL:**
- **Meropenem, ertapenem**

### **CRE = Very Limited Options:**
- **Ceftazidime-avibactam, meropenem-vaborbactam**

### **Hypervirulent *K. pneumoniae*:**
- **Liver abscess → metastatic spread** (endophthalmitis, meningitis)
- **Hypermucoviscous** (string test)

### **Clinical Pearls:**
- **Alcoholic pneumonia:** "Currant jelly" sputum, upper lobe
- **ESBL common:** Carbapenem (meropenem, ertapenem)
- **CRE:** Ceftazidime-avibactam, meropenem-vaborbactam (limited options)
- **hvKP:** Liver abscess + metastatic spread (endophthalmitis)
- **High mortality:** Bacteremic pneumonia (30-50%)

## Sources

- [CID: *Klebsiella pneumoniae* Infections 2024]
- [IDSA: CRE Management 2024]

## Media

N/A
